ESMO News

FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma

noreply@esmo.org — Mon, 19 Oct 2026 07:00:00 +0000

Evidence for efficacy is based on the results of the RASolute 302 study

Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL

noreply@esmo.org — Fri, 16 Oct 2026 07:54:00 +0000

Findings from the GIMEMA ALL2820 study

Meet the first recipient of the ESMO Artificial Intelligence Fellowship

noreply@esmo.org — Fri, 16 Oct 2026 07:00:00 +0000

EMA recommends granting a marketing authorisation for senaparib

noreply@esmo.org — Thu, 15 Oct 2026 07:00:00 +0000

It is intended for the maintenance treatment of advanced epithelial ovarian, Fallopian tube and primary peritoneal cancer

UN Pandemic Declaration Reflects Key ESMO Priorities

noreply@esmo.org — Wed, 14 Oct 2026 13:54:00 +0000

ESMO welcomed the adoption of the United Nations Political Declaration on Pandemic Prevention, Preparedness and Response (PPPR) on 12 October 2026, which resonates with several priorities that ESMO has consistently advocated for since the COVID-19 pandemic

Cancer vaccines and the next frontier in melanoma: From headlines to scientific evidence

noreply@esmo.org — Wed, 14 Oct 2026 08:29:00 +0000

FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma

noreply@esmo.org — Wed, 14 Oct 2026 07:00:00 +0000

FDA also approved two companion diagnostic devices

Five-year survival outcomes with neoadjuvant therapy in melanoma demonstrate that neoadjuvant ICIs exceeded adjuvant benchmarks

noreply@esmo.org — Tue, 13 Oct 2026 07:00:00 +0000

Findings from updated pooled analysis

Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor

noreply@esmo.org — Mon, 12 Oct 2026 07:00:00 +0000

Findings from the evERA study

EMA recommends granting a marketing authorisation for ensartinib

noreply@esmo.org — Fri, 09 Oct 2026 07:00:00 +0000

It is intended for the treatment of adult patients with ALK-positive, advanced NSCLC

Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection

noreply@esmo.org — Thu, 08 Oct 2026 07:00:00 +0000

Findings from the ROAM/EORTC-1308 study

ESMO Calls for the European Commission to Propose an EU Directive on Psychosocial Risks (PSR) at Work to Protect the Oncology Workforce

noreply@esmo.org — Wed, 07 Oct 2026 11:34:00 +0000

ESMO welcomes the adoption by the European Parliament (EP) Plenary on 6 October 2026 of the legislative report Psychosocial Risks, Stress and Mental Health at Work, marking an important milestone in securing the wellbeing, safety and resilience of Europe's cancer workforce

ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event

noreply@esmo.org — Wed, 07 Oct 2026 08:00:00 +0000

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

noreply@esmo.org — Wed, 07 Oct 2026 07:00:00 +0000

Evidence for efficacy is based on the results from the EXCALIBER-RRMM study

Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile

noreply@esmo.org — Tue, 06 Oct 2026 07:00:00 +0000

Findings from the PATHFINDER 2 study

Anito-cel, a d-domain BCMA CAR T-cell, induces rapid, deep, and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma

noreply@esmo.org — Mon, 05 Oct 2026 07:00:00 +0000

Findings from the first-in-human phase I study

EMA recommends granting a marketing authorisation for relacorilant

noreply@esmo.org — Fri, 02 Oct 2026 07:00:00 +0000

It is intended for the treatment of adult patients with epithelial ovarian, Fallopian tube or primary peritoneal cancer

Annual multicancer early detection test not associated with a lower incidence rate of stage III or IV cancer after three screening rounds and 12 months of follow-up

noreply@esmo.org — Thu, 01 Oct 2026 07:00:00 +0000

Findings from the the NHS-Galleri study

ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU measures to improve cancer care and halt the trend of growing cases in Europe

noreply@esmo.org — Wed, 30 Sep 2026 13:47:00 +0000

A robust implementation of Europe’s Beating Cancer Plan is essential to improve cancer prevention and early detection, enhance the quality of cancer treatments, and ultimately drive back cancer cases across the EU.

European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care

noreply@esmo.org — Wed, 30 Sep 2026 08:06:00 +0000

The adopted text reinforces clinically grounded procurement, governance and solidarity mechanisms to safeguard continuity of treatment as negotiations begin between the European Parliament, Council and Commission